Erratum
In the Review entitled “Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias” by Jabbour, Cortes & Kantarjian, published in the May 2007 issue of Expert Opinion on Investigational Drugs (Expert Opin. Investig. Drugs (2007) 16(5):679-687), it has been brought to our attention that the first paragraph of Section 4 should have read as follows:
The inter-relationship between BCR-ABL and the Src family TKs has been used to develop dasatinib (formerly BMS-354825 [Bristol-Myers Squibb: Sprycel™ (dasatinib tablets) prescribing information. Bristol-Myers Squibb, Princeton, New Jersey, USA (2006)]) aimed at improving CML treatment, including that for imatinib-resistant or -intolerant patients.
It has also been brought to our attention that the third paragraph of Section 4 should have read as follows
Dasatinib has recently been approved by the FDA for use as a single agent in the treatment of adults with CML (CP, AP or BP [myeloid or lymphoid]) or with Ph-positive acute lymphoblastic leukaemia (ALL), with resistance or intolerance to prior therapy, including imatinib (Bristol-Myers Squibb: Sprycel™ dasatinib tablets] prescribing information. Bristol-Myers Squibb, Princeton, New Jersey, USA (2006)).
We apologise for any inconvenience this may have caused our readers.